$4995 | Single User
$9990 | Site License
$14985 | Enterprise License

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments
[Lowest Price Guaranteed: $4,995]

Published by GBI Research: 11 Feb 2016 | 25764 | In Stock
Related Topics: Parkinson's Disease

Introduction

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

Summary

Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide.

Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell.

There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as off- time), which causes symptoms to return before the next dose.

With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.

Scope

- A brief introduction to Parkinson’s Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms

- Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy

- Comprehensive analysis of the pipeline for Parkinson’s Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target

- Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action

- Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain

- Discussion of the drivers of and barriers to market growth

- Discussion of the licensing and co-development deals landscape in Parkinson’s Disease (PD), by stage of development, molecule type and mechanism of action, as well as analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals

Reasons to buy

- Understand the different levels of Parkinson’s Disease (PD) therapy from early-stage to advanced

- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent

- Observe the trends in clinical trial duration and size among clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or forthcoming developmental programs for Parkinson’s Disease (PD) therapeutics

- Observe the trends in clinical trial duration and size among clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for Parkinson’s Disease (PD) therapeutics

- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the Parkinson’s Disease (PD) therapeutics market

Table of Contents
for Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

  • 1 Table of Contents

    1 Table of Contents 5

    1.1 List of Tables 7

    1.2 List of Figures 7

    2 Introduction 9

    2.1 Disease Introduction 9

    2.2 Symptoms 9

    2.3 Etiology 10

    2.3.1 Genetic Factors 10

    2.3.2 Environmental Factors 11

    2.3.3 Aging 11

    2.4 Pathophysiology 12

    2.5 Epidemiology 13

    2.6 Disease Stages 14

    2.7 Co-morbidities and Complications 15

    2.8 Diagnosis 15

    2.9 Assessment of Disease Severity 16

    2.9.1 Hoehn and Yahr scale 16

    2.9.2 Unified Parkinson’s Disease Rating Scale 16

    2.10 Treatment 17

    2.10.1 Pharmacological Therapies 18

    2.10.2 Non-pharmacological Treatments 20

    2.11 Treatment Algorithm 21

    2.11.1 Early Parkinson’s Disease 21

    2.11.2 Advanced Parkinson’s Disease 22

    3 Marketed Products 25

    3.1 Overview 25

    3.1.1 Dopamine Replacement Therapies 25

    3.1.2 MAO-B Inhibitors 28

    3.1.3 Dopamine Agonists 30

    3.1.4 COMT Inhibitors 35

    3.1.5 Other Drugs Targeting Non-motor Symptoms of PD 39

    3.2 Comparative Efficacy and Safety 40

    4 Pipeline for Parkinson’s Disease 44

    4.1 Overview 44

    4.2 Pipeline Distribution by Mechanism of Action/Molecular Target 46

    4.3 Clinical Trials 49

    4.3.1 Failure Rate 49

    4.3.2 Clinical Trial Duration 51

    4.3.3 Clinical Trial Size 53

    4.3.4 Comparison of Average Trial Metrics by Phase and Mechanism of Action 55

    4.4 Promising Pipeline Molecules 56

    4.4.1 Opicapone – Bial 56

    4.4.2 Nuplazid (pimavanserin) – Acadia Pharmaceuticals 58

    4.4.3 Nurelin (Amantadine Hydrochloride Extended-Release) – Adamas Pharmaceuticals 59

    4.4.4 Tozadenant – Biotie Therapies 60

    4.4.5 APL-130277 (apomorphine hydrochloride) – Cynapsus Therapeutics 61

    4.4.6 P2B001 (pramipexole dihydrochloride + rasagiline mesylate) – Pharma Two B 63

    4.4.7 DM-1992 (levodopa + carbidopa extended release) – Depomed 63

    4.4.8 CVT-301 (levodopa) – Acorda Therapeutics 65

    4.4.9 Dipraglurant Immediate-Release– Addex Therapeutics 65

    4.4.10 Accordion Pill (levodopa and carbidopa) – Intec Pharma 66

    4.4.11 ND-0612L (levodopa and carbidopa) – NeuroDerm 67

    4.5 Heatmaps of Safety and Efficacy for Parkinson’s Disease Pipeline and Marketed Products 69

    4.6 Pipeline Product Heat Map and Product Competitiveness Framework 73

    5 Market Forecast to 2021 74

    5.1 Geographical Markets 74

    5.1.1 Global Market 74

    5.1.2 North America 76

    5.1.3 Top Five European Markets 79

    5.1.4 Japan 84

    5.2 Drivers and Barriers 85

    5.2.1 Drivers 85

    5.2.2 Barriers 86

    6 Strategic Consolidations 88

    6.1 Major Co-Development Deals 88

    6.1.1 TechnoPhage Enters into Co-Development Agreement with University of Macau 90

    6.1.2 Dainippon Sumitomo Pharma Enters into Research Agreement with CiRA and Hitachi 90

    6.1.3 MJFF Enters into Agreement with Prothena 90

    6.1.4 Ubiquigent Enters into Co-Development Agreement with UbiQ 91

    6.1.5 23andMe Partners with Genentech 91

    6.2 Major Licensing Deals 91

    6.2.1 Cephalon Enters Into Licensing Agreement With Mesoblast For Regenerative Medicine 93

    6.2.2 Dexcel Pharma Enters into Licensing Agreement with Ramot at Tel Aviv University 94

    6.2.3 Neuropore Therapies Enters into Licensing Agreement with UCB 94

    6.2.4 Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences 94

    6.2.5 MedGenesis Therapeutix Enters into Licensing Agreement with Pfizer 95

    7 Appendix 96

    7.1 All Pipeline Drugs by Stage of Development 96

    7.1.1 Discovery 96

    7.1.2 Preclinical 100

    7.1.3 IND/CTA-filed 112

    7.1.4 Phase I 113

    7.1.5 Phase II 115

    7.1.6 Phase III 117

    7.1.7 Pre-registration 118

    7.2 Market Forecasts to 2021 118

    7.2.1 Global 118

    7.2.2 US 118

    7.2.3 Canada 119

    7.2.4 UK 119

    7.2.5 France 119

    7.2.6 Germany 120

    7.2.7 Italy 120

    7.2.8 Spain 120

    7.2.9 Japan 121

    7.3 References 121

    7.4 Abbreviations 129

    7.5 Research Methodology 132

    7.6 Secondary Research 133

    7.7 Marketed Product Profiles 133

    7.8 Late-Stage Pipeline Candidates 133

    7.9 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 134

    7.10 Product Competitiveness Framework 134

    7.11 Pipeline Analysis 134

    7.11.1 Overall Pipeline 134

    7.11.2 Clinical Trials 134

    7.11.3 Failure Rate 134

    7.11.4 Clinical Trial Size 135

    7.11.5 Clinical Trial Duration 135

    7.11.6 Forecasting Model 135

    7.12 Deals Data Analysis 136

    7.13 Expert Panel Validation 136

    7.14 Contact Us 136

    7.15 Disclaimer 136

List Of Tables
in Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

1.1 List of Tables

Table 1: Gene Mutations Related to Parkinson’s Disease and Corresponding Clinical Phenotypes 12

Table 2: Hoehn and Yahr Scale and the Definition of Disability Stages 16

Table 3: Unified Parkinson’s Disease Rating Scale 16

Table 4: All Pipeline Products by Phase, Discovery 96

Table 5: All Pipeline Products by Phase, Preclinical 100

Table 6: All Pipeline Products by Phase, IND/CTA-filed 112

Table 7: All Pipeline Products by Phase, Phase I 113

Table 8: All Pipeline Products by Phase, Phase II 115

Table 9: All Pipeline Products by Phase, Phase III 117

Table 10: All Pipeline Products by Phase, Phase III and Pre-registration 118

Table 11: Global, Parkinson's Disease Market Forecast, 2014–2021 118

Table 12: US, Parkinson's Disease Market Forecast, 2014–2021 118

Table 13: Canada, Parkinson's Disease Market Forecast, 2014–2021 119

Table 14: UK, Parkinson's Disease Market Forecast, 2014–2021 119

Table 15: France, Parkinson's Disease Market Forecast, 2014–2021 119

Table 16: Germany, Parkinson's Disease Market Forecast, 2014–2021 120

Table 17: Italy, Parkinson's Disease Market Forecast, 2014–2021 120

Table 18 : Spain, Parkinson's Disease Market Forecast, 2014–2021 120

Table 19: Japan, Parkinson's Disease Market Forecast, 2014–2021 121

List Of Figures, Charts and Diagrams
in Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments

1.2 List of Figures

Figure 1: Overview of the Basal Ganglia in the Normal State and Parkinson’s Disease State 13

Figure 2: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 1) 41

Figure 3: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products (Part 2) 42

Figure 4: Pipeline for Parkinson’s Disease, Global, 2015 45

Figure 5: Pipeline for Parkinson’s Disease by Molecular Target, Global, 2015 46

Figure 6: Pipeline for Parkinson’s Disease by Mechanism of Action, Global, 2015 47

Figure 7: Parkinson’s Disease, Global, Average Clinical Trial Failure Rate (%), 2006–2015 49

Figure 8 : Parkinson’s Disease, Global, Clinical Trial Failure Rates for Small Molecules (%), 2006–2015 50

Figure 9: Parkinson’s Disease, Global, Clinical Trial Failure Rates by Mechanism of Action (%), 2006–2015 51

Figure 10: Parkinson’s Disease, Global, Clinical Trial Duration by Molecule Type, 2006–2015 52

Figure 11: Parkinson’s Disease, Global, Clinical Trial Duration by Mechanism of Action, 2006–2015 53

Figure 12: Parkinson’s Disease, Global, Clinical Trial Size by Molecule Type, 2006–2015 54

Figure 13: Parkinson’s Disease, Global, Clinical Trial Size by Mechanism of Action, 2006–2015 55

Figure 14: Pipeline for Parkinson’s Disease, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action, 2006–2015 56

Figure 15: Parkinson’s Disease Market, Global, Annual Sales of Opicapone ($m), 2015–2021 57

Figure 16: Parkinson’s Disease Market, Global, Annual Sales of Nuplazid ($m), 2016–2021 59

Figure 17 : Parkinson’s Disease Market, Global, Annual Sales of Nurelin ($m), 2016–2021 60

Figure 18: Parkinson’s Disease Market, Global, Annual Sales of Tozadenant ($m), 2018–2021 61

Figure 19: Parkinson’s Disease Market, Global, Annual Sales of APL-130277 ($m), 2017–2021 62

Figure 20: Parkinson’s Disease Market, Global, Annual Sales of P2B001 ($m), 2016–2021 63

Figure 21: Parkinson’s Disease Market, Global, Annual Sales of DM-1992 ($m), 2018–2021 64

Figure 22: Parkinson’s Disease Market, Global, Annual Sales of CVT-301 ($m), 2016–2021 65

Figure 23: Parkinson’s Disease Market, Global, Annual Sales of Dipraglurant IR ($m), 2019–2021 66

Figure 24: Parkinson’s Disease Market, Global, Annual Sales of the Accordion Pill ($m) 2018–2021 67

Figure 25: Parkinson’s Disease Market, Global, Annual Sales of ND-0612L ($m) 2019–2021 68

Figure 26: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products 70

Figure 27: Parkinson’s Disease Market, Global, Efficacy Heat Map for Pipeline Products 70

Figure 28: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products 71

Figure 29: Parkinson’s Disease Market, Global, Efficacy Heat Map for Marketed Products 72

Figure 30: Parkinson’s Disease Market, Global, Product Competitiveness Early Parkinson’s Disease 73

Figure 31: Parkinson’s Disease Market, Global, Product Competitiveness Advanced Parkinson’s Disease 73

Figure 32: Parkinson’s Disease Market, Global, Treatment Patterns by Number of Patients (‘000), 2014–2021 75

Figure 33: Parkinson’s Disease Market, Global, Market Size ($m), 2014–2021 75

Figure 34: Parkinson’s Disease Market, US and Canada, Treatment Patterns by Number of Patients (‘000), 2014–2021 76

Figure 35: Parkinson’s Disease Market, US and Canada, Annual Cost of Therapy ($), 2014–2021 78

Figure 36: Parkinson’s Disease Market, US and Canada, Market Size ($), 2014–2021 79

Figure 37: Parkinson’s Disease Market, Top Five EU Countries, Treatment Patterns by Number of Patients (‘000), 2014–2021 80

Figure 38: Parkinson’s Disease Market, Tope Five EU Countries, Annual Cost of Therapy ($m), 2014–2021 82

Figure 39: Parkinson’s Disease Market, Top Five EU Countries, Market Size ($m), 2014–2021 83

Figure 40: Parkinson’s Disease Market, Japan, Treatment Patterns by Number of Patients (‘000) and the Annual Cost of Therapy ($), 2014–2021 84

Figure 41: Parkinson’s Disease Market, Japan, Market Size ($m), 2014–2021 85

Figure 42: Parkinson’s Disease Market, Global, Co-development Deals, 2006–2015 88

Figure 43: Parkinson’s Disease Market, Global, Co-development Deals by Molecule type and Stage of Development, 2006–2015 89

Figure 44: Parkinson’s Disease Market, Global, Co-development Deals by Mechanism of Action, 2006–2015 90

Figure 45: Parkinson’s Disease Market, Global, Licensing Deals, 2006–2015 92

Figure 46: Parkinson’s Disease Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2015 93

Figure 47: Parkinson’s Disease Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2015 93

Additional Details

Publisher

GBI Research

Publisher Information

Reference

25764 |

Number of Pages

136

Report Format

PDF

GBI Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Parkinson's Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Parkinson's Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Michael J. Fox Foundation for Parkinson's Research - Medical Equipment - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
16 Aug 2016 by Global Data USD $250 More Info
Michael J. Fox Foundation for Parkinson's Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
27 Apr 2016 by Global Data USD $250 More Info
Michael J. Fox Foundation for Parkinson's Research - Medical Equipment - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
15 Apr 2016 by Global Data USD $250 More Info
Michael J. Fox Foundation for Parkinson's Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
14 Mar 2016 by Global Data USD $250 More Info
Michael J. Fox Foundation for Parkinson's Research - Medical Equipment - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
25 Feb 2016 by Global Data USD $250 More Info
Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments
Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards D...
11 Feb 2016 by GBI Research USD $4,995 More Info
Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Parkinson’s Disease - Identifying and Commercializing First-in-Class InnovationSumm...
01 Jan 2016 by GBI Research USD $6,995 More Info
Michael J. Fox Foundation for Parkinson's Research - Medical Equipment - Deals and Alliances Profile
SummaryMichael J. Fox Foundation for Parkinson's Research (Michael J. Fox) is a research foundation ...
23 Oct 2015 by Global Data USD $250 More Info

This report is published by GBI Research

Download Free Report Summary PDF

Parkinson’s Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...